Drug Approval | May 08, 2024
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Subscribe To Our Newsletter & Stay Updated
